Transcriptomic Screening Platform

About Arpeggio Biosciences

Arpeggio Biosciences, founded in 2016 and based in Boulder, Colorado, is a private, pre-clinical biotech integrating AI with functional transcriptomic screening to discover small molecule drugs. The company has raised over $60 million from top life-sciences investors to advance its platform, which aims to systematically identify compounds that modulate disease-driving transcription factors and biological networks. Led by a seasoned team with deep pharmaceutical industry experience, Arpeggio is building a pipeline with an initial emphasis on lung cancer, targeting a high-value but historically challenging class of proteins.

Therapeutic Areas